Skip to main content
Erschienen in: Supportive Care in Cancer 9/2016

25.04.2016 | Original Article

International field testing of the psychometric properties of an EORTC quality of life module for oral health: the EORTC QLQ-OH15

verfasst von: Marianne J. Hjermstad, Mia Bergenmar, Kristin Bjordal, Sheila E. Fisher, Dirk Hofmeister, Sébastien Montel, Ourania Nicolatou-Galitis, Monica Pinto, Judith Raber-Durlacher, Susanne Singer, Iwona M. Tomaszewska, Krzysztof A. Tomaszewski, Irma Verdonck-de Leeuw, Noam Yarom, Julie B Winstanley, Bente B. Herlofson, on behalf of the EORTC QoL Group

Erschienen in: Supportive Care in Cancer | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This international EORTC validation study (phase IV) is aimed at testing the psychometric properties of a quality of life (QoL) module related to oral health problems in cancer patients.

Methods

The phase III module comprised 17 items with four hypothesized multi-item scales and three single items. In phase IV, patients with mixed cancers, in different treatment phases from 10 countries completed the EORTC QLQ-C30, the QLQ-OH module, and a debriefing interview. The hypothesized structure was tested using combinations of classical test theory and item response theory, following EORTC guidelines. Test–retest assessments and responsiveness to change analysis (RCA) were performed after 2 weeks.

Results

Five hundred seventy-two patients (median age 60.3, 54 % females) were analyzed. Completion took <10 min for 84 %, 40 % expressed satisfaction that these issues were addressed. Analyses suggested a revision of the phase III hypothesized scale structure. Two items were deleted based on a high degree of item misfit, together with negative patient feedback. The remaining 15 items formed one eight-item scale named OH-QoL score, a two-item information scale, a two-item scale regarding dentures, and three single items (sticky saliva/mouth soreness/sensitivity to food/drink). Face and convergent validity and internal consistency were confirmed. Test–retest reliability (n = 60) was demonstrated as was RCA for patients undergoing chemotherapy (n = 117; p = 0.06). The resulting QLQ-OH15 discriminated between clinically distinct patient groups, e.g., low performance status vs. higher (p < 000.1), and head-and-neck cancer versus other cancers (p < 0.03).

Conclusion

The EORTC module QLQ-OH15 is a short, well-accepted assessment tool focusing on oral problems and QoL to improve clinical management.

Trial Registration

ClinicalTrials.​gov Identifier: NCT01724333.
Literatur
1.
Zurück zum Zitat NIH State-of-the-Science Statement on symptom management in cancer: Pain, depression, and fatigue (2002). NIH Consens State Science Statements 19(4): 1–29 NIH State-of-the-Science Statement on symptom management in cancer: Pain, depression, and fatigue (2002). NIH Consens State Science Statements 19(4): 1–29
2.
Zurück zum Zitat U.S.Department of Health and Human services NIoH. National Cancer Institute: The NCI strategic plan for leading the nation. To eliminate the suffering and death due to cancer (2006). In: U.S.Department of Health and Human services NIoH, ed., Bethesda, MD, US, Free-eBooks.net U.S.Department of Health and Human services NIoH. National Cancer Institute: The NCI strategic plan for leading the nation. To eliminate the suffering and death due to cancer (2006). In: U.S.Department of Health and Human services NIoH, ed., Bethesda, MD, US, Free-eBooks.​net
3.
Zurück zum Zitat Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD (2013) Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 309(8):814–822CrossRefPubMed Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD (2013) Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 309(8):814–822CrossRefPubMed
4.
Zurück zum Zitat Jensen SB, Pedersen AM, Vissink A, Andersen E, Brown CG, Davies AN, et al. (2010) A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer 18(8):1039–1060CrossRefPubMed Jensen SB, Pedersen AM, Vissink A, Andersen E, Brown CG, Davies AN, et al. (2010) A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer 18(8):1039–1060CrossRefPubMed
5.
Zurück zum Zitat Epstein JB, Thariat J, Bensadoun RJ, Barasch A, Murphy BA, Kolnick L, et al. (2012) Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin 62(6):400–422CrossRefPubMed Epstein JB, Thariat J, Bensadoun RJ, Barasch A, Murphy BA, Kolnick L, et al. (2012) Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin 62(6):400–422CrossRefPubMed
6.
Zurück zum Zitat Villa A, Wolff A, Narayana N, Dawes C, Aframian DJ, Lynge Pedersen AM, Vissink A, et al. (2015) World workshop on oral medicine VI: a systematic review of medication-induced salivary gland dysfunction. Oral Dis. doi:10.1111/odi.12402 Villa A, Wolff A, Narayana N, Dawes C, Aframian DJ, Lynge Pedersen AM, Vissink A, et al. (2015) World workshop on oral medicine VI: a systematic review of medication-induced salivary gland dysfunction. Oral Dis. doi:10.​1111/​odi.​12402
7.
Zurück zum Zitat Epstein JB, Jensen SB (2015) Management of hyposalivation and xerostomia: criteria for treatment strategies. Compend Contin Educ Dent 36(8):600–603PubMed Epstein JB, Jensen SB (2015) Management of hyposalivation and xerostomia: criteria for treatment strategies. Compend Contin Educ Dent 36(8):600–603PubMed
8.
Zurück zum Zitat Furness S, Worthington HV, Bryan G, Birchenough S, McMillan R (2011) Interventions for the management of dry mouth: topical therapies. Cochrane Database Syst Rev 12:CD008934PubMed Furness S, Worthington HV, Bryan G, Birchenough S, McMillan R (2011) Interventions for the management of dry mouth: topical therapies. Cochrane Database Syst Rev 12:CD008934PubMed
9.
Zurück zum Zitat Furness S, Bryan G, McMillan R, Birchenough S, Worthington HV (2013) Interventions for the management of dry mouth: non-pharmacological interventions. Cochrane Database Syst Rev 9:CD009603PubMed Furness S, Bryan G, McMillan R, Birchenough S, Worthington HV (2013) Interventions for the management of dry mouth: non-pharmacological interventions. Cochrane Database Syst Rev 9:CD009603PubMed
10.
Zurück zum Zitat Jensen SB, Pedersen AM, Vissink A, Andersen E, Brown CG, Davies AN, et al. (2010) A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact. Support Care Cancer 18(8):1061–1079CrossRefPubMed Jensen SB, Pedersen AM, Vissink A, Andersen E, Brown CG, Davies AN, et al. (2010) A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact. Support Care Cancer 18(8):1061–1079CrossRefPubMed
11.
Zurück zum Zitat Heckel M, Stiel S, Ostgathe C (2015) Smell and taste in palliative care: a systematic analysis of literature. Eur Arch Otorhinolaryngol 272(2):279–288CrossRefPubMed Heckel M, Stiel S, Ostgathe C (2015) Smell and taste in palliative care: a systematic analysis of literature. Eur Arch Otorhinolaryngol 272(2):279–288CrossRefPubMed
13.
Zurück zum Zitat Hong CH, Napenas JJ, Hodgson BD, Stokman MA, Mathers-Stauffer V, Elting LS, et al. (2010) A systematic review of dental disease in patients undergoing cancer therapy. Support Care Cancer 18(8):1007–1021CrossRefPubMedPubMedCentral Hong CH, Napenas JJ, Hodgson BD, Stokman MA, Mathers-Stauffer V, Elting LS, et al. (2010) A systematic review of dental disease in patients undergoing cancer therapy. Support Care Cancer 18(8):1007–1021CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Elad S, Epstein JB, Raber-Durlacher J, Donnelly P, Strahilevitz J (2012) The antimicrobial effect of Iseganan HCl oral solution in patients receiving stomatotoxic chemotherapy: analysis from a multicenter, double-blind, placebo-controlled, randomized, phase III clinical trial. J Oral Pathol Med 41(3):229–234CrossRefPubMed Elad S, Epstein JB, Raber-Durlacher J, Donnelly P, Strahilevitz J (2012) The antimicrobial effect of Iseganan HCl oral solution in patients receiving stomatotoxic chemotherapy: analysis from a multicenter, double-blind, placebo-controlled, randomized, phase III clinical trial. J Oral Pathol Med 41(3):229–234CrossRefPubMed
15.
Zurück zum Zitat Lalla RV, Latortue MC, Hong CH, Ariyawardana A, D’Amato-Palumbo S, Fischer DJ, et al. (2010) A systematic review of oral fungal infections in patients receiving cancer therapy. Support Care Cancer 18(8):985–992CrossRefPubMedPubMedCentral Lalla RV, Latortue MC, Hong CH, Ariyawardana A, D’Amato-Palumbo S, Fischer DJ, et al. (2010) A systematic review of oral fungal infections in patients receiving cancer therapy. Support Care Cancer 18(8):985–992CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Al-Dasooqi N, Sonis ST, Bowen JM, Bateman E, Blijlevens N, Gibson RJ, et al. (2013) Emerging evidence on the pathobiology of mucositis. Support Care Cancer 21(11):3233–3234CrossRefPubMed Al-Dasooqi N, Sonis ST, Bowen JM, Bateman E, Blijlevens N, Gibson RJ, et al. (2013) Emerging evidence on the pathobiology of mucositis. Support Care Cancer 21(11):3233–3234CrossRefPubMed
18.
Zurück zum Zitat Riley P, Glenny AM, Worthington HV, Littlewood A, Clarkson JE, McCabe MG (2015) Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy. Cochrane Database Syst Rev 12:CD0115 Riley P, Glenny AM, Worthington HV, Littlewood A, Clarkson JE, McCabe MG (2015) Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy. Cochrane Database Syst Rev 12:CD0115
19.
Zurück zum Zitat Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo TMB, O’Ryan F (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg 72(10):1938–1956CrossRefPubMed Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo TMB, O’Ryan F (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg 72(10):1938–1956CrossRefPubMed
20.
Zurück zum Zitat Schuurhuis JM, Stokman MA, Witjes MJ, Dijkstra PU, Vissink A, Spijkervet FK (2015) Evidence supporting pre-radiation elimination of oral foci of infection in head and neck cancer patients to prevent oral sequelae. A systematic review. Oral Oncol 51(3):212–220CrossRefPubMed Schuurhuis JM, Stokman MA, Witjes MJ, Dijkstra PU, Vissink A, Spijkervet FK (2015) Evidence supporting pre-radiation elimination of oral foci of infection in head and neck cancer patients to prevent oral sequelae. A systematic review. Oral Oncol 51(3):212–220CrossRefPubMed
21.
Zurück zum Zitat Epstein JB, Parker IR, Epstein MS, Gupta A, Kutis S, Witkowski DM (2007) A survey of National Cancer Institute-designated comprehensive cancer centers’ oral health supportive care practices and resources in the USA. Support Care Cancer 15(4):357–362CrossRefPubMed Epstein JB, Parker IR, Epstein MS, Gupta A, Kutis S, Witkowski DM (2007) A survey of National Cancer Institute-designated comprehensive cancer centers’ oral health supportive care practices and resources in the USA. Support Care Cancer 15(4):357–362CrossRefPubMed
22.
Zurück zum Zitat Ohrn KE, Wahlin YB, Sjoden PO, Wahlin AC (1996) Indications for and referrals to oral care for cancer patients in a county hospital. Acta Oncol 35(6):743–748CrossRefPubMed Ohrn KE, Wahlin YB, Sjoden PO, Wahlin AC (1996) Indications for and referrals to oral care for cancer patients in a county hospital. Acta Oncol 35(6):743–748CrossRefPubMed
23.
Zurück zum Zitat Wilberg P, Hjermstad MJ, Ottesen S, Herlofson BB (2014) Chemotherapy-associated oral sequelae in patients with cancers outside the head and neck region. J Pain Symptom Manag 48(6):1060–1069CrossRef Wilberg P, Hjermstad MJ, Ottesen S, Herlofson BB (2014) Chemotherapy-associated oral sequelae in patients with cancers outside the head and neck region. J Pain Symptom Manag 48(6):1060–1069CrossRef
24.
Zurück zum Zitat Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, et al. (2014) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120(10):1453–1461CrossRefPubMedPubMedCentral Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, et al. (2014) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120(10):1453–1461CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Gamper EM, Zabernigg A, Wintner LM, Giesinger JM, Oberguggenberger A, Kemmler G, et al. (2012) Coming to your senses: detecting taste and smell alterations in chemotherapy patients. A systematic review. J Pain Symptom Manag 44(6):880–895CrossRef Gamper EM, Zabernigg A, Wintner LM, Giesinger JM, Oberguggenberger A, Kemmler G, et al. (2012) Coming to your senses: detecting taste and smell alterations in chemotherapy patients. A systematic review. J Pain Symptom Manag 44(6):880–895CrossRef
26.
Zurück zum Zitat Hjermstad MJ, Bergenmar M, Fisher SE, Montel S, Nicolatou-Galitis O, Raber-Durlacher J, et al. (2012) The EORTC QLQ-OH17: a supplementary module to the EORTC QLQ-C30 for assessment of oral health and quality of life in cancer patients. Eur J Cancer 48(14):2203–2211CrossRefPubMed Hjermstad MJ, Bergenmar M, Fisher SE, Montel S, Nicolatou-Galitis O, Raber-Durlacher J, et al. (2012) The EORTC QLQ-OH17: a supplementary module to the EORTC QLQ-C30 for assessment of oral health and quality of life in cancer patients. Eur J Cancer 48(14):2203–2211CrossRefPubMed
28.
Zurück zum Zitat DeWolf L, Koller M, Velikova G, Jokovic A, Scott N, Bottomley A (2009) EORTC quality of life group translation procedure, 3rd edn. EORTC Study Group on Quality of Life, Brussels ISBN 978–2–930064-38-3 DeWolf L, Koller M, Velikova G, Jokovic A, Scott N, Bottomley A (2009) EORTC quality of life group translation procedure, 3rd edn. EORTC Study Group on Quality of Life, Brussels ISBN 978–2–930064-38-3
29.
Zurück zum Zitat Johnson C, Aaronson N, Blazeby J, Bottomley A, Fayers P, Koller M, et al. (2011) Guidelines for developing questionnaire modules, 4th edn. EORTC Quality of Life Group, Brussels ISBN 978–2–930064-413 Johnson C, Aaronson N, Blazeby J, Bottomley A, Fayers P, Koller M, et al. (2011) Guidelines for developing questionnaire modules, 4th edn. EORTC Quality of Life Group, Brussels ISBN 978–2–930064-413
30.
Zurück zum Zitat Karnofsky D, Abelmann W, Craver L, Burchenal J (1948) The use of nitrogen mustard in the palliative treatment of cancer. Cancer 1(4):634–656CrossRef Karnofsky D, Abelmann W, Craver L, Burchenal J (1948) The use of nitrogen mustard in the palliative treatment of cancer. Cancer 1(4):634–656CrossRef
31.
Zurück zum Zitat Streiner DL, Norman GR (2003) Health measurement scales: a practical guide to their development and use, 3rd edn. Oxford University Press, Oxford Streiner DL, Norman GR (2003) Health measurement scales: a practical guide to their development and use, 3rd edn. Oxford University Press, Oxford
32.
Zurück zum Zitat Pallant JF, Tennant A (2007) An introduction to the Rasch measurement model: an example using the Hospital Anxiety and Depression Scale (HADS). Br J Clin Psychol 46(Pt 1):1–18CrossRefPubMed Pallant JF, Tennant A (2007) An introduction to the Rasch measurement model: an example using the Hospital Anxiety and Depression Scale (HADS). Br J Clin Psychol 46(Pt 1):1–18CrossRefPubMed
33.
Zurück zum Zitat Smith EV Jr (2002) Detecting and evaluating the impact of multidimensionality using item fit statistics and principal component analysis of residuals. J Appl Meas 3(2):205–231PubMed Smith EV Jr (2002) Detecting and evaluating the impact of multidimensionality using item fit statistics and principal component analysis of residuals. J Appl Meas 3(2):205–231PubMed
34.
Zurück zum Zitat Bjordal K, Ahlner-Elmqvist M, Tollesson E, Jenssen AB, Razavi D, Maher EJ, et al. (1994) Development of a European Organization for Research and Treatment of Cancer (EORTC) questionnaire module to be used in quality of life assessments in head and neck patients. Acta Oncol 33:879–885CrossRefPubMed Bjordal K, Ahlner-Elmqvist M, Tollesson E, Jenssen AB, Razavi D, Maher EJ, et al. (1994) Development of a European Organization for Research and Treatment of Cancer (EORTC) questionnaire module to be used in quality of life assessments in head and neck patients. Acta Oncol 33:879–885CrossRefPubMed
35.
Zurück zum Zitat Vivat B, Young T, Efficace F, Sigurdardottir V, Arraras JI, Asgeirsdottir GH, et al. (2013) Cross-cultural development of the EORTC QLQ-SWB36: a stand-alone measure of spiritual wellbeing for palliative care patients with cancer. Palliat Med 5:457–469CrossRef Vivat B, Young T, Efficace F, Sigurdardottir V, Arraras JI, Asgeirsdottir GH, et al. (2013) Cross-cultural development of the EORTC QLQ-SWB36: a stand-alone measure of spiritual wellbeing for palliative care patients with cancer. Palliat Med 5:457–469CrossRef
36.
Zurück zum Zitat Sodergren SC, White A, Efficace F, Sprangers M, Fitzsimmons D, Bottomley A, et al. (2014) Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group. Crit Rev Oncol Hematol 91(1):35–46CrossRefPubMed Sodergren SC, White A, Efficace F, Sprangers M, Fitzsimmons D, Bottomley A, et al. (2014) Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group. Crit Rev Oncol Hematol 91(1):35–46CrossRefPubMed
37.
Zurück zum Zitat Wheelwright S, Darlington AS, Fitzsimmons D, Fayers P, Arraras JI, Bonnetain F, et al. (2013) International validation of the EORTC QLQ-ELD14 questionnaire for assessment of health-related quality of life elderly patients with cancer. Br J Cancer 109(4):852–858CrossRefPubMedPubMedCentral Wheelwright S, Darlington AS, Fitzsimmons D, Fayers P, Arraras JI, Bonnetain F, et al. (2013) International validation of the EORTC QLQ-ELD14 questionnaire for assessment of health-related quality of life elderly patients with cancer. Br J Cancer 109(4):852–858CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Basch E, Deal AM, Kris MG, Scher HI, Hulis CA, Sabbatini P, et al. (2015) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34(6):557–565CrossRefPubMed Basch E, Deal AM, Kris MG, Scher HI, Hulis CA, Sabbatini P, et al. (2015) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34(6):557–565CrossRefPubMed
Metadaten
Titel
International field testing of the psychometric properties of an EORTC quality of life module for oral health: the EORTC QLQ-OH15
verfasst von
Marianne J. Hjermstad
Mia Bergenmar
Kristin Bjordal
Sheila E. Fisher
Dirk Hofmeister
Sébastien Montel
Ourania Nicolatou-Galitis
Monica Pinto
Judith Raber-Durlacher
Susanne Singer
Iwona M. Tomaszewska
Krzysztof A. Tomaszewski
Irma Verdonck-de Leeuw
Noam Yarom
Julie B Winstanley
Bente B. Herlofson
on behalf of the EORTC QoL Group
Publikationsdatum
25.04.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 9/2016
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3216-0

Weitere Artikel der Ausgabe 9/2016

Supportive Care in Cancer 9/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.